N/A N=110 Functional Electrical Stimulation for Footdrop in Hemiparesis
Stroke · Hemiplegia
Primary: Fugl-Meyer Motor Assessment (FMA) — 20.1; 20.3; 21.5; 21.18 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=22 Phytosterols, Ezetimibe, and Cholesterol Metabolism
Hypercholesterolemia · Coronary Heart Disease
Primary: Cholesterol Excretion — 505; 794; 962 mg per day — p=0.01
N/A N=120 EDWARDS INTUITY Valve System CADENCE Study
Aortic Valve Disease · Aortic Stenosis
Primary: Average Subject Time Spent on Cardiopulmonary Cross Clamp — 77.5; 82.0 Minutes — p=0.3660
Phase 2 N=36 Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
N/A N=14 Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat
Stability & Variability of Lipid-derived Molecules in Sweat
Primary: Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation — 20; 46; 2.2; 3.5 picomoles per milliliter
Phase 2 N=73 Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
Alzheimer's Disease · Sleep Disorder
Primary: Change From Baseline to 24 Weeks in ADAS-cog — 0.45; 0.19 Scores on a scale
Phase 4 N=550 Subcuticular Suture for Cesarean Skin Incision Closure
Complications; Cesarean Section · Surgical Wound Infection
Primary: Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc) — 23; 37; 16; 25 Participants — p=0.04
Phase 4 N=124 Salt Loading and Thiazide Intervention Study
Hypertension
Primary: Blood Pressure Change During Salt Loading — -25.5; 34.6; 23.2; -41.4 mmHg — p=>0.05
Phase 2 N=24 RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Leukemia · Acute Lymphocytic Leukemia
Primary: Maximum Tolerated Dose [MTD] Determination by Number of Participants With Dose Limiting Toxicity (DLT) — 0; 1 Participants
N/A N=34 Single Breath Hold Abdominal MRI
Abdominal MRI
Primary: Motion Artifact Scores — 1.8; 2.4 scores on a scale — p=<0.001
Phase 4 N=16 Metformin in Longevity Study (MILES).
Aging
Primary: Increase in Number of Expressed Genes in Muscle and Adipose Tissue Using RNA Sequencing (RNA-Seq) — 245; 402; 15; 132 genes
Phase 2 N=100 Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer
Primary: Recurrence-free Survival — 98 percentage of subjects
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
Phase 2 N=81 Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Leukemia · Myeloproliferative Diseases
Primary: Number of Participants With Complete Response (CR) — 19 Participants
Phase 3 N=308 Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26 — -1.12; -1.18 Percentage of total hemoglobin — p=0.0002